seperator

Pipeline Status

seperator

The initial focus of Ethris is to leverage our pioneering SNIM® RNA technology platform to develop therapies for severe pulmonary diseases, especially those with high unmet need such as Primary Ciliary Dyskinesia (PCD). Beyond this, the versatility of our first-in-class biopharmaceutical platform for replacing or augmenting missing or non-functional proteins will ultimately enable us to address an array of diverse respiratory diseases.

Find out more about our lead candidate, ETH42, here.

Learn more about our technology.

GO TO TECHNOLOGY